Intensity Therapeutics, Inc.
INTS
$6.49
$0.172.69%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.18M | 1.16M | 1.21M | 1.24M | 1.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.73M | 2.71M | 3.39M | 3.20M | 3.57M |
| Operating Income | -2.73M | -2.71M | -3.39M | -3.20M | -3.57M |
| Income Before Tax | -2.67M | -2.54M | -3.35M | -3.18M | -3.51M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.67M | -2.54M | -3.35M | -3.18M | -3.51M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.67M | -2.54M | -3.35M | -3.18M | -3.51M |
| EBIT | -2.73M | -2.71M | -3.39M | -3.20M | -3.57M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.55 | -3.36 | -5.51 | -5.52 | -6.36 |
| Normalized Basic EPS | -0.97 | -2.10 | -3.45 | -3.45 | -3.98 |
| EPS Diluted | -1.55 | -3.36 | -5.51 | -5.52 | -6.36 |
| Normalized Diluted EPS | -0.97 | -2.10 | -3.45 | -3.45 | -3.98 |
| Average Basic Shares Outstanding | 1.72M | 754.70K | 606.90K | 576.00K | 552.20K |
| Average Diluted Shares Outstanding | 1.72M | 754.70K | 606.90K | 576.00K | 552.20K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |